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INTRODUCTION
Depressive disorders are highly prevalent throughout the 
world.
1 Depressive disorders often impair social and occupa-
tional function and cause a considerable social burden.
2-4 The 
optimal use of medications including antidepressants in the 
treatment of depressive disorders may reduce the social bur-
den of depression as well as individual distress. For many years 
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after antidepressants were introduced for treatment for depres-
sion, tricyclic antidepressants (TCAs) were the first-line treat-
ment of choice for depressive disorders. However, over the 
past decade, the first-line agent in the treatment of depression 
has shifted from TCAs to selective serotonin reuptake inhibi-
tors (SSRIs).
5,6 A number of previous reviews have found that 
TCAs and SSRIs have comparable efficacy but that SSRIs are 
generally better tolerated than TCAs.
7,8 On the other hand, 
when newer antidepressants were recently introduced, they 
were expected to have superior efficacy compared with SSRIs 
because of their different mechanisms of action, including 
dual action or non-serotonergic action. A recent meta-analy-
sis reported that serotonergic-noradrenergic antidepressants, 
so-called dual-action antidepressants, including venlafaxine 
and mirtazapine, seem to have a modest efficacy advantage 
over SSRIs.
9 However, further systematic research is needed to 
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confirm the superior efficacy of newer antidepressants in spe-
cific sub-populations of patients with depressive disorders or 
specific depressive symptoms. Despite the considerable devel-
opment of antidepressants, recent studies suggested that many 
patients do not achieve a satisfactory outcome, and no single 
treatment strategy seems to be a panacea in the treatment of 
depressive disorders.
10 Obviously, there is a pressing need to 
develop more effective treatments for depression.
To enhance treatment success rates, the most appropriate 
antidepressants should be selected according to symptoms and 
patient characteristics. Many factors have been reported to in-
fluence the choice of antidepressant prescribed by clinicians, 
including the severity of depression, previous depressive epi-
sodes, the presence of comorbid conditions, and previous use 
of antidepressants.
6,11-13 In cases of non-response or partial re-
sponse, several treatment strategies are currently recommend-
ed as a next-step treatment, including switching to another an-
tidepressant, combining two antidepressants, and using other 
agents concomitantly.
12,14 Clinicians who treat patients with 
depression need to be kept abreast of the newer treatment 
strategies, and the need for a more understanding of these 
practices is clear.
Increasing numbers and types of antidepressant are now av-
ailable in the Korean marketplace, so the armamentarium of 
antidepressant medications has expanded considerably. How-
ever, little is known about current prescribing practices in Ko-
rea in the treatment of depressive disorders. Most previous 
studies on antidepressant prescription practices in Korea have 
been in the form of survey research; although such studies 
might reflect preferred treatment strategies, they do not show 
real prescription patterns in actual clinical settings. To the 
best of our knowledge, there has been no nationwide pro-
spective study on prescription patterns in the treatment of 
depressive disorders in actual practice settings in Korea.
The Clinical Research Center for Depression (CRESC-
END) study is the first long-term prospective clinical study on 
depression in Korea, with a large nationwide sample popula-
tion and government support. It is a naturalistic study in real-
world practice settings investigating characteristics, courses of 
treatment, and outcomes in Korean patients with depressive 
disorders. Using the data from this study, the analyses presen-
ted here were carried out to investigate antidepressant pre-
scribing patterns for the treatment of depressive disorders in 
real clinical settings over a 12-week treatment period.
METHODS
Study overview
The design and procedure of the study have also been de-
scribed elsewhere.
15 In total, 18 hospitals (16 university and 2 
general hospitals) are collaborating in the ongoing CRE-
SCEND study. The central coordinating center is located in 
the Psychiatric Department of the Catholic University Medi-
cal Center in Seoul and provides educational support and co-
ordination for the enrollment and follow-up of study partici-
pants. The data-management center is in the Preventative 
Medicine Department of the Catholic University College of 
Medicine and provides support for obtaining data and quality 
control. Other regional centers located across South Korea 
play a role in recruitment and follow-up. With respect to the 
selection of regional centers, a nationwide distribution was 
sought, and at least two hospitals that were anticipated to be 
assessing and treating the largest numbers of people with de-
pressive disorders (as opposed to hospitals primarily provid-
ing inpatient care for people with chronic psychotic disorders) 
were recruited from each province. Availability of personnel 
and study facilities were also taken into consideration. Enrol-
ment took place in a naturalistic clinical environment and dr-
ew from both outpatient and inpatient settings, regardless of 
depression subtypes and physical comorbidity. Treatment in-
terventions were also conducted in a naturalistic fashion with 
full autonomy for each clinician in determining the type, dose, 
and regimen of antidepressant and other medications. Assess-
ments were scheduled at baseline, at 1, 2, 4, 8, 12, 24, and 52 
weeks post-baseline, and annually thereafter. At each visit, a 
clinical review took place to decide treatment modalities. All 
other data on socio-demographic, clinical, and treatment-re-
lated characteristics were obtained by clinical research coordi-
nators, who were trained and certified in clinical report form 
(CRF) implementation and data collection methods by the 
central coordinating center and supervised by the clinicians 
of the regional centers. Participants’ data were recorded on a 
predetermined CRF at each visit, entered in the website home-
page of the CRESCEND study (www.smileagain.or.kr) within 
two days, and monitored by personnel of the data-manage-
ment center.
Subjects
All patients who visited the study hospitals seeking treat-
ment for depression were candidate subjects for the study. Pa-
tients were assessed and diagnosed based on the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV)
16 criteria. Patients who were diagnosed with de-
pressive disorders according to these diagnostic criteria were 
invited to participate in the study. All patients who agreed to 
take part in the study provided written informed consent. No 
advertising was used for the recruitment of subjects, and they 
received no economic compensation for study participation. 
The period for baseline recruitment was from January 2006 to 
August 2008.236  Psychiatry Investig 2011;8:234-244
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The CRESCEND study used broad inclusion criteria and 
minimal exclusion criteria to reflect real-world practices in 
Korea. Inclusion criteria were out- and inpatients aged over 7 
years who were diagnosed with depressive disorders accord-
ing to DSM-IV. Although there was no limitation to the base-
line 17-item Hamilton Depression Rating Scale
17 (HAMD) 
scores in the CRESCEND study, only patients with HAMD 
scores greater than 14 were included for the present analysis. 
Exclusion criteria were a history of comorbid DSM-IV diag-
noses of psychotic disorders including schizophrenia, bipolar 
disorders, and dementia; any significant medical or neurolog-
ical illnesses; and women who were currently pregnant or 
breastfeeding. 
The study was approved by all relevant university and hospi-
tal institutional review boards. All participants reviewed the 
consent form, and written informed consent was obtained by 
research staff before participation in the study. For participants 
aged less than 16 years, written consent was obtained from a 
parent or legal guardian, and written assent was obtained from 
the participant. For those who were very old or physically ill, 
the nature and purpose of the study were explained, and writ-
ten informed consent was obtained from the person or his/her 
caregiver, as appropriate.
Socio-demographic and clinical characteristics
Socio-demographic characteristics were evaluated by a 
clinical research coordinator using the structured CRF. Data 
were obtained on age, gender, duration of formal education, 
marital status, cohabiting status, religious observation, current 
occupation, and monthly income. For this analysis, the follow-
ing categories were applied: marital status (currently married 
or not), cohabiting status (living alone or not), religion (reli-
gious observance or not), occupation (currently employed or 
not), and monthly income (above or below 2,000 USD).
As mentioned above, depressive disorder diagnoses were 
made by the treating clinicians based on DSM-IV criteria. In 
a sub-sample of patients who gave consent, the DSM-IV based 
Structured Clinical Interview
18 (SCID) was administered for 
confirmation. Depressive disorders were divided into four 
groups: i) major depressive disorder without psychotic fea-
tures, ii) major depressive disorder with psychotic features, iii) 
dysthymic disorder, and iv) depressive disorder not otherwise 
specified. The clinical research coordinators assessed all other 
clinical characteristics at baseline using the structured CRF: 
setting at enrollment (outpatient or inpatient), history of pre-
vious depressive episodes (recurrent or first episode), number 
of previous depressive episodes, age at onset and duration of 
illnesses, family history of depression, history of suicide at-
tempt, and concurrent physical disorder. To determine suicide 
attempt history, participants were asked if suicide had ever 
been attempted, with supplementary questions about the 
method and severity of the attempt. Information on physical 
disorders was gathered using a questionnaire enquiring about 
33 different disorders, which was recoded for this analysis as 
the presence or absence of any physical disorder.
Further assessment scales for evaluating symptoms and 
function were administered by the clinical research coordina-
tors. The instruments administered were the HAMD, the Ha-
milton Anxiety Rating Scale
19 (HAMA), the Clinical Global 
Impression Scale-severity scale
20 (CGI-s), and the Social and 
Occupational Functioning Assessment Scale
16 (SOFAS). All 
assessment scales have been formally translated and standard-
ized in Korean.
21-22
Drug treatment
Drug treatment was performed in naturalistic patterns 
based on each clinician’s decision; that is, all clinicians who 
participated in this study themselves decided on the prescrip-
tions of antidepressants and concomitant medications, consid-
ering each patient’s condition. All types, regimens, and doses 
of antidepressants were allowed by the study. Clinicians decid-
ed on treatment modalities according to patients’ states at 
each visit. 
For the purpose of the analyses, antidepressants were clas-
sified as follows: SSRIs (citalopram/escitalopram, paroxetine, 
fluoxetine, sertraline); newer dual-action antidepressants (mir-
tazapine, venlafaxine, bupropion); other antidepressants in-
cluding TCAs (milnacipran, imipramine, amitriptyline, nor-
triptyline, dothiepine, trazodone). Treatment regimens were 
classified into monotherapy, switching, and combination. 
Monotherapy was defined as using only one antidepressant 
during the treatment period. Switching was defined as switch-
ing from one to another antidepressant, and combination was 
defined as the use of two or more antidepressants for most of 
the treatment period.
Any concomitant medications used to enhance efficacy and 
relieve associated symptoms of depression or to control ad-
verse effects were allowed, according to the clinicians’ deci-
sion. These were classified into antipsychotics, mood stabiliz-
ers, and anxiolytics/hypnotics. Antipsychotics included ris-
peridone, olanzapine, quetiapine, aripirazole, amisulpride, 
ziprasidone, perphenazine, haloperidol, and pimozide. Mood 
stabilizers were lithium and valproic acid, an anticonvulsant. 
Anxiolytics/hypnotics were lorazepam, alprazolam, diazepam, 
clonazepam, clorazepate, ethyl loflazepate, zolpidem, flunitraz-
epam, and bromazepam. Other concomitant agents such as 
buspirone were also prescribed.
Statistical analyses
The results described here are restricted to data obtained in KY Bae et al. 
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the initial 12 weeks of treatment in order to focus on the acute 
treatment of depressive disorders. We present the results in 
number and percentage (%) form for descriptive data using 
tables and figures. 
We investigated the type of antidepressant(s) prescribed at 
the baseline visit and divided the treatment strategies used 
during the 12-week period of our investigation into mono-
therapy; switching, i.e., switching to another antidepressant; 
and combination, i.e., concomitant use of other agents besides 
antidepressants (augmentation) and concomitant use of anti-
depressants (combination). The use of anxiolytic/hypnotics 
during the study period was also investigated. In addition, in-
formation on the timing of switching, augmentation, and 
combination therapy was collected. These prescription pat-
terns were compared again by the treatment setting, baseline 
HAMD and HAMA scores, and psychotic features using χ2 or 
Fisher’s exact tests.
RESULTS
Patient sample and baseline characteristics
A total of 1,183 patients were enrolled in the CRESCEND 
study, and data from 723 (61%) patients were eligible for the 
present analysis; that is, these patients scored more than 14 on 
the HAMD and were taking antidepressants for up to 12 
weeks, following the clinical decision of a clinician. Patients 
who had one or more visits after the baseline evaluation were 
included in the analysis. Patients disposition by hospitals and 
provinces was as follow: 181 at the Saint Mary’s Hospital of 
the Catholic University, 243 at the Korea University Hospital, 
28 at the Soonchunhyang University Hospital, 25 at the Han-
yang University Hospital, and 2 at the Samsung Medical Cen-
Table 1. Demographic and clinical characteristics of the study population
Total sample (N=723)
Socio-demographic characteristics
Age, mean (SD) years 48.4 (16.0)
Gender, N (%) female  535 (74.0)
Education, mean (SD) years 10.3 (4.7)
Marital status, N (%) married  469 (64.9)
Living alone, N (%)    94 (13.0)
Religion, N (%) have  424 (58.6)
Occupation, N (%) no  466 (64.5)
Monthly income, N (%) <2,000 USD  356 (49.2)
Clinical characteristics
Diagnosis Major depressive disorder without psychotic feature  591 (81.7)
Major depressive disorder with psychotic feature    18 (2.5)
Dysthymic disorder    21 (2.9)
Depressive disorder not otherwise specified    93 (12.9)
Setting at enrollment, N (%) outpatients  572 (79.1)
Recurrent depression, N (%)  301 (41.6)
Number of depressive episodes, median (IQR)    1.0 (1-2)
Age at onset, mean (SD) years 44.7 (17.2)
Duration of illness, median (IQR) years   1.0 (1-4)
Family history of depression, N (%)    99 (13.7)
History of suicide attempt, N (%)  163 (22.5)
Physical disorders, N (%) have  247 (34.2)
Assessment scales, mean (SD) scores
Hamilton Depression Rating Scale 21.6 (4.9)
Hamilton Anxiety Rating Scale 20.2 (8.4)
Clinical Global Impression-severity   4.8 (1.0)
Social and Occupational Functional Assessment Scale 57.1 (11.0)
N: number, SD: standard deviation, USD: United States dollar, IQR: interquartile range238  Psychiatry Investig 2011;8:234-244
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ter located in Seoul; 39 at the Kangwon National University 
Hospital in Kangwon province; 89 at the Kyemyung Universi-
ty Hospital and 1 at the Kyungpook National University Hos-
pital in Daegu; 1 at the Inje University Paik hospital and 1 at 
the Marynoll Hospital in Busan; 60 at the Chonnam National 
University Hospital and 12 at the Chosun University Hospital 
in Gwangju; and 41 at the Hwasun Chonnam National Uni-
versity Hospital in Jeollanam province.
Baseline socio-demographic and clinical characteristics of 
the patients are shown in Table 1. Most of the patients were 
female (74%), were diagnosed as having major depressive dis-
order without psychotic features (82%), and were enrolled 
from outpatient settings (79%). Over half were believed to be 
first-episode cases. The patients included in our analysis 
(n=723) did not differ from those excluded with respect to 
any sociodemographic or clinical characteristics (all p-values 
>0.15). However, the scores on all assessment scales suggested 
more severe symptoms or pathology in those included (all p-
values <0.001), reflecting our inclusion criterion of HAMD 
score ≥14.
Prescribing patterns
Choice of antidepressant at baseline 
Figure 1 shows the pattern of initial antidepressant choice. 
SSRIs were the most commonly prescribed initial antidepres-
sant (48.9% of all patients), followed by newer dual-action an-
tidepressants (45.8% of all patients). The most commonly pre-
scribed antidepressants among the SSRIs were escitalopram 
(22.4%) and paroxetine (18.7%), followed by fluoxetine (4.1%) 
and sertraline (3.7%). With regard to newer dual-action anti-
depressants, mirtazapine or venlafaxine is prescribed for 
43.9% of all patients. Only 1.9% of patients were treated with 
bupropion. Other antidepressants including milnacipran, 
imipramine, amitriptyline, tianeptine, and moclobemide were 
initially prescribed for 5.3% of all patients.
With respect to prescribing patterns by the treatment set-
ting, the initial antidepressants prescribed for inpatients were 
48.3% SSRIs, 45.7% newer dual-action antidepressants, and 
6.0% other antidepressants; and for outpatients were 49.3% 
SSRIs, 45.8% newer dual-action antidepressants, 4.9% other 
antidepressants. There were no significant differences in the 
choice of initial antidepressant between the inpatients (n=151) 
and outpatients (n=572) (p=0.866). In addition, the HAMD 
and HAMA scores did not affect the choice of initial antide-
pressant [HAMD score ≥22 (n=324) vs. <22 (n=399), p=0.179; 
and HAMA score ≥20 (n=339) vs. <20 (n=384), p=0.63]. 
Treatment pattern at the next step
According to the data, regardless of the initial antidepres-
sant prescribed, the largest proportion of patients received an-
tidepressant monotherapy for most of the study period. Over-
all, 67.6% to 71.3% of patients were maintained on anti-
depressant monotherapy according to the initial antidepress-
ants. Combination treatment with more than one antidepress-
ant was used for 24.3% to 26.0% of patients. Switching from 
the initial antidepressant to another antidepressant occurred 
in 3.7% to 8.1% of patients.
The pattern of antidepressant switching
When an SSRI was initially prescribed, 38.5% of patients 
were switched to other SSRIs, and 46.2% and 15.3% were 
switched to newer dual-action antidepressants and other anti-
depressants, respectively. When a newer dual-action or other 
antidepressant was the initial antidepressant, 70.6% of patients 
taking newer dual-action antidepressants and 66.7% of those 
taking other antidepressants, respectively, were switched to 
SSRIs; 23.5% of prescriptions for newer dual-action drugs 
were changed to another dual-action drug, and 33.3% of pre-
scriptions for other medications were switched to a newer du-
al-action antidepressant. The proportion of patients switching 
from newer dual-action antidepressants to other antidepres-
sants including TCAs was only 5.9% (Figure 2). When the ini-
tial antidepressants were switched to non-SSRI agents, venla-
faxine (21.2%) was most commonly chosen among newer 
dual-action antidepressants, followed by mirtazapine (6.1%), 
bupropion (6.1%); switching to other antidepressants com-
prised only 9% of overall switching to non-SSRIs (milnacipran, 
3%; imipramine, 3%; and amitriptyline, 3%). Overall, the most 
commonly chosen switching strategy was switching to SSRIs 
(54.5%), followed by switching to newer dual-action antide-
pressants (33.4%) and to other antidepressants including 
Figure 1. The prescribing pattern of antidepressants as first-line 
treatment.
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TCAs (9%). In terms of individual antidepressant, venlafax-
ine, a kind of serotonin/norepinephrine reuptake inhibitor 
(SNRI), was most commonly chosen (21.2%), followed by SS-
RIs including escitalopram (18.2%), paroxetine (15.2%), and 
sertraline (15.2%). There were no significant differences in the 
pattern of switching to individual antidepressants by the treat-
ment setting (inpatient vs. outpatient, p=0.446), the HAMD 
score (HAMD score ≥22 vs. <22, p=0.137) and HAMA score 
(HAMA score ≥20 vs. <20, p=0.145).
The pattern of combination antidepressant treatment
When SSRIs were initially prescribed, 67.4% of initial SSRIs 
were combined with newer dual-action antidepressants, and 
22.5% and 10.1% were combined with other antidepressants 
including TCAs and other SSRIs, respectively. When newer 
dual-action antidepressants were the initial antidepressant, 
other antidepressants including TCAs were most commonly 
added for combination treatment (50%), followed by other 
newer dual-action antidepressants (28.1%) and SSRIs (20.9%). 
When other antidepressants including TCAs were initially 
prescribed, newer dual-action antidepressants were most 
commonly added (44.5%), followed by SSRIs (33.3%) and 
other antidepressants including TCAs (22.2%) (Figure 3). The 
most frequently used combination strategy was the newer du-
al-action antidepressants (47.8%), followed by the other anti-
depressants including TCAs (35.9%) regardless of the initial 
antidepressants. The antidepressant most frequently added to 
initiate combination therapy was amitriptyline (29.9%), a 
TCA, followed by the newer dual-action antidepressants in-
cluding mirtazapine (19.6%), bupropion (17.9%), and venla-
faxine (10.3%). There were no significant differences in the 
pattern of added antidepressants by the treatment setting (in-
patient vs. outpatient, p=0.563), the HAMD score (HAMD 
score ≥22 vs. <21, p=0.379) and HAMA score (HAMA score 
≥20 vs. <20, p=0.082).
The pattern of concomitant medication
Of all prescriptions for antidepressants, 20.6% were aug-
mented by other agents, and of these, 75.1% were used con-
comitantly with anxiolytics or hypnotics. The rates of concom-
itant medication according to the class of antidepressant are 
shown in Figure 4. The most frequently used concomitant 
medication was an antipsychotic agent (56.4%), and quetiap-
ine was the most frequently used of the available antipsychot-
ic medications (29.5%). Antipsychotic agents were given in 91 
(12.9%) depressive patients without psychotic features. Buspi-
rone was frequently added to the antidepressant (28.2%), and 
lithium (8.1%) and anticonvulsants (7.4%) were also frequent-
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ly used as concomitant medications. In terms of the concomi-
tant use of benzodiazepines, lorazepam (48.4%) and alprazol-
am (36%) were the benzodiazepines most frequently used 
concomitantly with the antidepressants. There were significant 
differences in the pattern of concomitant medication by the 
treatment setting. Lithium was more frequently prescribed in 
the inpatient setting (25.9%) than the outpatient one (4.1%) 
and buspirone was less frequently prescribed in the inpatient 
setting (7.4%) than the outpatient one (32.8%) (inpatient vs. 
outpatient, p<0.001). However, there were no significant dif-
ferences in the pattern of concomitant medication by the 
HAMD score (HAMD score ≥22 vs. <21, p=0.489) and HAMA 
score (HAMA score ≥20 vs. <20, p=0.339). The prescription 
rate of anxiolytics or hypnotics is higher in patients with HA-
MD score ≥22 (80.9%) compared to HAMD score <21 (70.4%), 
(p=0.001).
Timing of combination therapy, concomitant  
medication, and switching
Most physicians (91%) tended to use anxiolytics or hypnot-
ics concomitantly from the beginning of antidepressant treat-
ment. A considerable portion (56.4%) of the concomitant use 
of other agents besides antidepressants started within 1 week 
of beginning treatment. However, 42.4% of antidepressant 
switching occurred after 2 weeks of treatment, and 36.4% and 
21.2% of switching occurred after 3 and 4 weeks of treatment, 
respectively. With respect to initiation of combination treat-
ment, 38% of such combinations were started during the first 
week of treatment, and 27.7% and 14.7% were started during 
weeks 2 and 3, respectively. Only 19.6% of combination treat-
ments were started during week 8.
DISCUSSION
Data on the prescription of antidepressants in real-world 
psychiatric practice in Korea is limited. Most previous studies 
have used survey research or investigated the prescribing pat-
tern in just one hospital. The CRESCEND study was planned 
to reflect the actual psychiatric clinical picture throughout Ko-
rea and its strength is that it is representative of Korea in terms 
of both sample size and the source of patients. To our knowl-
edge, this study was the first nationwide prospective clinical 
study on Korean patients with depressive disorders. The re-
sults of this study show that many changes have occurred in 
Korean psychiatrists’ prescribing of antidepressants. 
A previous study in Korea, reported in 2003, found that SS-
RIs were preferred by many psychiatrists (70%) as first-line 
agents for the treatment of major depressive disorder (MDD), 
and a much lower proportion of respondents (8%) preferred 
newer dual-action antidepressants, including mirtazapine and 
venlafaxine.
23 However, the results of the present study show 
that SSRIs were actually prescribed as first-line agents for only 
48.9% of patients with MDD, and the rate of the prescription 
of newer dual-action antidepressants seems to have increased 
significantly, to 45.8%. Mirtazapine was the most frequently 
prescribed antidepressant (26.6%). Jung et al.
23 suggested that 
newer dual-action antidepressants had not yet been proven 
safe and effective when they were introduced into Korea in the 
late 1990s, and therefore many psychiatrists preferred SSRIs, 
which had been demonstrated to be effective and safe agents. 
However, as Korean psychiatrists’ cumulative experience in 
using newer dual-action antidepressants including mirtazap-
ine has grown, prescription of these drugs has increased. In 
particular, mirtazapine is significantly less likely to cause the 
sexual dysfunction that SSRIs commonly cause and is also ef-
fective, without adjunctive benzodiazepine, against the de-
creased appetite, sleep problems, anxiety, and agitation fre-
quently associated with MDD.
24 In addition, a recent meta-
analysis found that mirtazapine has a faster onset of action and 
higher remission rates than SSRIs in the first 6 weeks of treat-
ment. These findings may explain the rapid increase in the use 
of mirtazapine as a first-line agent.
25 
The present study showed that the use of venlafaxine has 
also increased. A recent meta-analysis suggested that venla-
faxine was associated with greater response (odds ratio 1.15) 
and remission (odds ratio 1.19) in the treatment of MDD, 
compared with SSRIs.
26 The study showed that the odds ratio 
for response and remission was 1.35 in treatment-resistant 
depression, compared with SSRIs.
Although venlafaxine is known to be associated with sym-
pathomimetic cardiovascular effects including hypertension 
and prolonged heart rate-corrected QT interval,
27 the signifi-
cant increase in the prescription of venlafaxine appears to re-
flect recent more aggressive trends in the prescription of an-
tidepressants. Many studies and meta-analyses have 
suggested that dual-action antidepressants including venla-
faxine and mirtazapine have superior efficacy over single-ac-
tion antidepressants.
28,29 Increased use of mirtazapine and 
venlafaxine in real practice seems to be related to the expec-
tation of a better response.
With regard to switching, when the initial antidepressants 
were SSRIs, the most common switch was to newer dual-ac-
tion antidepressants (46.2%) followed by switching to other 
SSRIs (38.5%). When the initial antidepressants were non-SS-
RIs, switching to SSRIs was most common (about 70%). In 
terms of individual agents, switching to venlafaxine, a newer 
dual-action antidepressant, was most common (21.2%), fol-
lowed by SSRIs including escitalopram (18.2%). The Korean 
Medication Algorithm for Major Depressive Disorder (KM-
AP- MD) suggests that switching from the initial antidepres-KY Bae et al. 
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sant to venlafaxine and other SSRIs is reasonable in patients 
who failed to respond to the initial antidepressant.
30 In partic-
ular, when the initial antidepressants are the newer dual-action 
types or TCAs, KMAP-MD recommends switching to SSRIs 
first, and this recommendation is concordant with the results 
of this study.
One notable finding of the present study concerns the tim-
ing of switching. Most current treatment guidelines for MDD 
recommend the continuous use of antidepressants for 4 to 8 
weeks.
11,14,31 KMAP-MD also recommends that switching sh-
ould be considered only after the continuous use of antide-
pressants for 3 to 5 weeks. The findings of this study showed 
that the actual mean switching time is 4.0±2.3 weeks. How-
ever, a considerable proportion of switching (42.4%) occurred 
within 2 weeks after initiation of treatment. This result is con-
sistent with findings by Seo et al.
32 who suggested that in-
creased pressure for early discharge seems to be affecting treat-
ment choices in inpatient settings. However, the findings of 
the present study show a similar trend in outpatient settings. 
A growing body of evidence suggests that response to antide-
pressant treatment in the first 2 weeks may be used as a pre-
dictor of subsequent outcomes. Therefore, it may be a useful 
strategy to switch antidepressants as early as possible instead of 
waiting for 4 to 8 weeks if patients do not respond quickly to 
treatment.
33,34 A recent meta-analysis suggested that the early 
clinical response (i.e., 2 weeks) could be a predictor of the sub-
sequent response and that there was little chance of a sustained 
response for patients who made no improvement within 2 
weeks.
35 In any case, the results of this study showed that sw-
itching time has been advanced in real practice, and system-
atic prospective studies in Korea are necessary to address this 
timing issue.
Among the patients in this study, 25% received antidepres-
sant combination treatment. The concomitant use of two an-
tidepressants is controversial because of possible adverse ef-
fects and questionable clinical benefits.
36 Current treatment 
guidelines for MDD usually recommend starting a single first-
line agent and trying a series of other single agents if patients 
fail to respond to the first one. However, the findings of this 
study showed a gap between the guidelines and real practice. 
We observed that some psychiatrists started combination tr-
eatment from the early phase of treatment. In this study, 38% 
of combination treatments started within 1 week of treatment 
commencing. The STAR*D (Sequenced Treatment Alterna-
tives to Relieve Depression) study suggested that consecutive 
monotherapy cannot be the best treatment strategy for pa-
tients who seem not to respond to an initial monotherapy.
37 
Blier et al.
38 reported that antidepressant combinations ap-
proximately doubled the remission rates achieved with single 
agent. In addition, NIMH (the National Institute of Mental 
Health) recently funded a study, Combining Oral Medica-
tions to End Depression (COMED), to compare the poten-
tial benefits of antidepressant combination treatment at initi-
ation of treatment. Evidence is accumulating that combi-
nation treatment from the very early phase of treatment may 
result in enhanced outcomes. Some researchers argue that 
this trend represents a major paradigm shift in the treatment 
of depression.
39
In terms of the classes of antidepressants that may be com-
bined, the present study found that when initial antidepres-
sants were SSRIs, newer dual-action antidepressants were 
most frequently prescribed as concomitant antidepressants 
(67.4%). A previous study to investigate the general practice of 
psychiatrists reported that SSRI plus mirtazapine was the most 
popular first-choice combination.
40 That study suggested that 
psychiatrists chose this option because of the anxiolytic and 
sleep-inducing effects, dual-action mechanism, good interac-
tion profile, rapid onset of action, and lack of typical SSRI side 
effects. The results of the present study also showed that, 
among newer dual-action antidepressants, mirtazapine was 
most commonly prescribed when a combination treatment 
was being considered. Another study on treatment given in a 
Korean university hospital reported that a combination treat-
ment of an SSRI plus a TCA was most frequently chosen in 
2001, but that in 2006, an SSRI plus mirtazapine was the most 
frequent combination, and a combination of mirtazapine and 
venlafaxine was often used in addition to the combination of 
an SSRI plus a TCA.
32 However in the present study, bupropi-
on was also frequently added to initial antidepressants (17.9%). 
Bupropion is an antidepressant with properties of norepineph-
rine- and dopamine-reuptake inhibition instead of serotoner-
gic action. The combination of bupropion and an SSRI or 
SNRI is widely used as an option that has a triple reuptake in-
hibitor-like action, and bupropion also seems to reverse cer-
tain adverse effects associated with serotonergic agents and to 
enhance the efficacy of initial antidepressants.
41,42 On the oth-
er hand, in this study when the initial antidepressants were 
newer dual-action and other antidepressants including TCAs, 
other (50%) and newer dual-action antidepressants (44.5%), 
respectively, were frequently chosen as the concomitant anti-
depressant. That is, the combination of newer dual-action an-
tidepressants plus other antidepressants including TCAs was 
commonly used.
Interestingly, however, amitriptyline was the most com-
monly used concomitant antidepressant (29.9%). Jung et al.
23 
reported that 90% of psychiatrists who responded to a survey 
were prescribing amitriptyline in 2003. Amitriptyline has mul-
tiple pharmacological actions. In addition to noradrenergic 
and serotonergic actions, amitriptyline also has some affinity 
for muscarinic and histaminergic systems.
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evidence indicates that amitriptyline has some adverse effects, 
it was most frequently prescribed as a first-line antidepressant 
in the past and was still the most commonly used concomitant 
antidepressant in this study. But the dose of amitriptyline was 
significantly lower (mean 12.3 mg/day) in this study than that 
usually used for the treatment of depressive disorders. This 
result suggests that the amitriptyline was being used to control 
associated symptoms such as sleep disorder, pain, and agita-
tion rather than to manage the depression itself. In general, the 
results of this study showed that combination strategies have 
diversified as new dual-action antidepressants have been in-
troduced into the market.
Augmentation treatment with non-antidepressant agents 
can be used to accelerate treatment response. We found that 
about 20% of patients received augmentation treatment and 
the most commonly used augmenting agent was an antipsy-
chotic. Atypical antipsychotic agents (52.3%) were more fre-
quently prescribed than were typical antipsychotics (4.1%). 
Growing evidence suggests that other atypical antipsychotics 
are also associated with antidepressant effects through 5-HT2 
receptor antagonism and 5-HT1A and dopamine receptor par-
tial agonistic activity.
44 Among the atypical antipsychotic 
agents in this study, quetiapine was the most commonly used 
(29.5%). This result is concordant with the result of a previous 
study. Seo et al.
32 suggested that an antidepressant effect of 
quetiapine started to receive attention because the effect of 
quetiapine on bipolar depression was demonstrated, and its 
use for this purpose was approved by the FDA (Food and 
Drug Administration). Quetiapine enhances central seroto-
nergic transmission through 5-HT2A receptor antagonism, 
and 5-HT1A receptor modulation is thought to be important 
in quetiapine’s antidepressant efficacy.
45,46 Dopamine trans-
mission is known to be enhanced in patients who are treated 
with quetiapine by antagonism of 5-HT2A and partial agonis-
tic activity at 5-HT1A.
47,48 In addition, previous studies have 
suggested that quetiapine may exert its antidepressant effect 
through effects on the glutamate receptor and norepineph-
rine transporter.
45 It has also been reported that concomitant 
use of quetiapine in the treatment of depression improves 
sleep disturbance and causes earlier onset of antidepressant 
action, which may ultimately lead to the reduction of suicide 
risk.
49 Other than quetiapine, aripiprazole has recently be-
come the first atypical antipsychotic agent to be approved by 
the FDA for the adjunctive treatment of MDD. It is thought 
that atypical antipsychotics will play a greater role in the 
treatment of depression in the future.
This study showed that buspirone accounted for 28.2% of all 
concomitant use of agents in the “other antidepressant” cate-
gory. Buspirone was first proposed for use in an augmentation 
strategy in the 1990s, but a controlled study found that the 
concomitant use of buspirone was no more effective than the 
addition of a placebo.
50 Buspirone augmentation looked prom-
ising in the STAR*D study, but the findings were unclear be-
cause the patient group who received buspirone augmenta-
tion had lower depressive symptoms at baseline.
51 Further 
systematic study is needed to demonstrate the ultimate effica-
cy of buspirone augmentation.
In another paper from the same dataset of our study group, 
we investigated the relationship between a history of a suicide 
attempt and treatment characteristics. In brief, we did not find 
significant difference between patients with and without a 
history of a suicide attempt in the choice of antidepressant or 
the use of concomitant medications including antipsychotic 
agent. However, mood stabilizers were more frequently pre-
scribed in patients with a history of a suicide attempt.
52
In terms of anxiolytics and hypnotics including benzodiaz-
epine, we found that about 75% of patients received benzodi-
azepine. A combination of antidepressant and benzodiaze-
pine appears to be common practice throughout the world. 
However, the advantages of this combination treatment are 
unclear. Fava et al.
53 recently reported that patients with MDD 
who were treated with fluoxetine plus the hypnotic eszopi-
clone showed more improvement on other depressive symp-
tom scores and on sleep scores than did patients treated with 
fluoxetine alone. The study also found that patients treated 
with both an antidepressant and hypnotic agent showed sig-
nificantly increased remission rates. The sleep-improving ef-
fects of hypnotics are suspected to enhance antidepressant ef-
ficacy.
39 The Cochrane review also reported that combination 
treatment with both antidepressant and benzodiazepine is 
more likely to result in a positive response than is treatment 
with antidepressant alone.
54 Therefore, the benefits of adding 
a benzodiazepine to antidepressant treatment should be bal-
anced judiciously against possible risks, including dependence 
and accident proneness. 
This study has some limitations. Firstly, this is an open-la-
bel naturalistic study for the treatment of depressive patients. 
The naturalistic design was both a strength and potential lim-
itation. The broad inclusion and minimal exclusion criteria 
for recruitment, and the absence of limitations placed on treat-
ment were designed to reflect real clinical situations as closely 
as possible and maximize generalizability to clinical practice. 
However, because the treatment modality was determined by 
the choice of the treating clinician rather than by any formal 
guideline, inter-clinician variability might affect observed out-
comes. Secondly, most patients were recruited from the uni-
versity hospitals (16 of 18 hospitals), which can affect the pre-
scription patterns. Lastly, approximately three-fourths of pa-
tients were enrolled from outpatient settings. There are possi-
bilities that patients who were enrolled were less severe and KY Bae et al. 
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treatment setting affected the prescription patterns. However, 
we found that there were no significant differences in the pre-
scription patterns according to the treatment setting (inpatient 
or outpatient).
Overall, the CRESCEND study, a nationwide naturalistic 
study, has several important implications for clinicians. Firstly, 
there is a gap between current treatment guidelines and real-
world practice. The results of this study show the real trends of 
prescription practice in Korea, namely, that the choice of anti-
depressants and the concomitant use of other agents have be-
come increasingly diversified as newer agents, such as dual-ac-
tion antidepressants and atypical antipsychotics, have been 
introduced into Korea. The concomitant use of antidepres-
sants and atypical antipsychotics including quetiapine has 
been increasing. In addition, the concomitant use of other 
agents seems to start from the early phase of treatment, and an 
early switching strategy is commonly used. Further systematic 
studies are required to develop new treatment guidelines for 
depression that are suited to Korean society today, that reflect 
changes in prescribing patterns in real practice, and that con-
sider new research evidence in the treatment of depression. In 
addition, further studies to compare the results of this study 
with those of the National Health Insurance database will be 
useful to examine the actual Korean antidepressants prescrip-
tion pattern.
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